Subcutaneous, intramuscular, oral, nasal—the route you choose changes the dose, the onset, and whether the peptide works at all.

Sources and References

Related Guides

Quick Facts

What “Route of Administration” Means—And Why It’s Not Just About Convenience

Route of administration is the physical pathway by which a compound enters your body and, eventually, reaches the tissues where it acts.

Most people think of route as a matter of convenience. Oral is easy—you swallow a pill. Injection requires a needle. IV requires medical supervision. Topical goes on your skin. So naturally, if something works via IV, maybe we can just switch to oral and get the same effect with better convenience, right?

This reasoning is the foundation of some of the most prevalent misinterpretations in peptide science.

The reason is this: the route you choose determines the physical and chemical journey your compound takes. That journey determines what percentage of your dose actually reaches systemic circulation, how quickly it gets there, how high the concentration spikes, how long it stays active, and what tissues it encounters along the way. Each of these variables changes the pharmacology—sometimes dramatically.

Here’s a concrete example. Suppose you read a study showing that a peptide healed wounds when injected directly into rat wounds. Then you read online that people are taking the same peptide orally to heal their gut. The two routes sound like they might be equivalent—both getting the peptide to the target tissue. But they’re not. Directly injected, the peptide reaches extremely high local concentrations at the exact site of injury. Taken orally, the peptide has to survive stomach acid and peptidase enzymes in the small intestine (most peptides don’t—they get shredded before they can be absorbed). If it somehow survives and gets absorbed, it enters the bloodstream and travels throughout the body. Only a tiny fraction reaches the gut in sufficient concentration to replicate the effect seen in the injection study. The compound that worked in the localized injection study is not the same pharmacological event as oral administration.

Route of administration is not a detail. It is a determinant of the drug itself.

↑ Back to top

The Major Routes Relevant to Peptides

Most peptides are administered via one of seven routes. Each has distinct pharmacological characteristics.

Subcutaneous Injection (SC, SQ, SubQ)

What it is: Injection into the subcutaneous tissue layer—the fatty tissue directly beneath the skin. This is the self-injection method used in many community peptide protocols and is the standard administration route for insulin, growth hormone, and many biologics.

Why peptide researchers prefer it: Subcutaneous tissue has rich blood supply but is not as immediately vascular as IV administration. This creates relatively high and sustained bioavailability (typically 50–100% for most peptides, though specific values vary by compound structure and formulation) with a gentler absorption curve than IV. For peptides, this is often the “Goldilocks” route—effective, relatively safe, and practical for self-administration.

Absorption kinetics: Peptides injected subcutaneously are absorbed into the bloodstream gradually over minutes to hours. The exact absorption rate depends on the peptide’s size, hydrophobicity, and the local blood flow at the injection site.

Intramuscular Injection (IM)

What it is: Injection directly into muscle tissue. Commonly used for vaccines and certain biologics.

Why it’s less common for peptides: Muscle tissue is highly vascular, creating rapid absorption similar to subcutaneous but with higher peak concentrations and shorter duration. For most peptides, this route doesn’t offer a practical advantage over subcutaneous injection, so it’s rarely the chosen route in designed protocols. Some community protocols use IM injection interchangeably with subcutaneous, but the pharmacology is distinct.

Absorption kinetics: Faster initial absorption than subcutaneous, with higher and more acute peak concentrations.

Intravenous Infusion (IV)

What it is: Injection directly into a vein, delivering the compound into the bloodstream immediately. Can be administered as a bolus (rapid injection) or infusion (slow, controlled drip).

Bioavailability: By definition, 100%. All of the dose reaches systemic circulation instantaneously.

Why it appears in clinical trials: IV administration offers the greatest precision and control. You know exactly when peak concentration occurs (immediately), and you can closely monitor the patient for adverse effects in real time. Regulatory agencies prefer IV for Phase I and Phase II trials because it minimizes pharmacokinetic variability.

Why it’s impractical for self-administration: IV injection requires aseptic technique, proper access (usually a venipuncture), and medical supervision. Self-directed IV administration is dangerous and illegal in most contexts. This is crucial: clinical trial evidence from IV administration does not transfer to subcutaneous self-administration, because the exposure kinetics are completely different.

Oral (Per Os)

What it is: Swallowing the compound. Absorption occurs through the gastrointestinal tract.

The challenge for peptides: Peptides are proteins—chains of amino acids. Your digestive system evolved to break down proteins into individual amino acids. The instant a peptide enters your stomach, it encounters hydrochloric acid and pepsin (a protease that cleaves peptide bonds). If it somehow survives the stomach and reaches the small intestine, it faces a hostile environment filled with additional peptidases—trypsin, chymotrypsin, carboxypeptidases—all designed to dismantle peptide bonds. Most peptides have zero meaningful oral bioavailability. Some estimates: oral bioavailability for unmodified peptides = typically < 1%.

The SNAC exception: Semaglutide (brand name Ozempic/Wegovy) is a GLP-1 receptor agonist that achieved approximately 1% oral bioavailability by being co-formulated with SNAC (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate). SNAC is a chemical permeation enhancer that locally increases the pH of the small intestine and reduces the activity of peptidases, allowing a tiny fraction of the semaglutide molecule to cross the intestinal epithelium. Even with this engineering, oral semaglutide achieves only ~1% of the bioavailability of subcutaneous semaglutide. This is not a design flaw—it’s the reality of peptide pharmacology. Most oral peptide claims in community spaces have no SNAC equivalent and therefore have near-zero bioavailability.

Absorption: Highly variable and highly compound-dependent. For unmodified peptides: assume low to negligible absorption unless the compound has been specifically engineered for oral bioavailability.

Nasal/Intranasal (IN)

What it is: Sprayed or insufflated into the nasal cavity. The nasal mucosa is highly vascular and permeable, allowing some compounds to cross directly into the bloodstream and also directly into cerebrospinal fluid via the olfactory nerve.

Why it matters: The nasal route offers a potential pathway to bypass first-pass metabolism and achieve CNS penetration that might not be possible via other routes. Some peptides show promise via intranasal administration in research settings.

Current status for peptides: Limited clinical use. Intranasal oxytocin has been studied in controlled trials for social cognition and bonding behavior, and intranasal vasopressin has early human trial data, but neither has FDA approval via this route. Selank and Semax (Russian nootropic peptides) are administered intranasally in their approved formulations. Not commonly used in community peptide protocols.

Topical (Trans-Dermal, Cream, Solution)

What it is: Applied to the skin surface. Absorption through the skin barrier depends on the compound’s molecular weight, hydrophobicity, and formulation.

Bioavailability: Highly variable. Most peptides have very low trans-dermal bioavailability due to their size and hydrophilicity (peptides are generally water-loving and don’t easily cross the lipid-rich skin barrier). Some peptides are formulated as topical creams or solutions intended for local skin effects without systemic absorption. Others use penetration enhancers or liposomal encapsulation to increase absorption.

Critical distinction: Topical application can produce either local effects (the peptide stays in the skin and local tissues) or systemic effects (the peptide crosses the skin barrier and enters circulation). These are pharmacologically distinct applications. GHK-Cu topical cosmetic formulations are designed for local skin effects. Injectable GHK-Cu is designed for systemic circulation. They are different applications with different evidence bases.

Intravitreal (IVT)

What it is: Direct injection into the vitreous humor of the eye. Used clinically for certain ophthalmologic conditions.

Why it’s unique: Intravitreal injection creates an extremely high local concentration at the target tissue (the retina) while producing near-zero systemic exposure. The blood-retinal barrier prevents systemic circulation entirely. This is a pharmacologically isolated space—what happens in the eye stays in the eye.

Why it matters for peptides: Some peptides are being researched for retinal disease via intravitreal injection. The pharmacology is completely distinct from systemic administration (IV, subcutaneous, oral). Local high-dose intravitreal delivery is not comparable to systemic delivery at lower doses. This is relevant to the Vision/Ocular peptide cluster on Peptidings, where the distinction between local (eye) and systemic delivery must be carefully maintained.

↑ Back to top

Bioavailability: The Percentage That Actually Reaches Systemic Circulation

Bioavailability is the fraction of an administered dose that reaches systemic circulation (your bloodstream) in unchanged form.

IV administration, by definition, has 100% bioavailability. All of the dose reaches the bloodstream immediately.

Every other route has lower bioavailability. How much lower depends on the compound and the route.

Subcutaneous injection of peptides: Typically 50–100%, depending on the peptide structure and formulation. Most peptides are designed for subcutaneous administration and achieve reasonably high bioavailability. However, specific bioavailability values are not always published for research peptides. This is a significant data gap.

Oral peptides (unmodified): Typically < 1%. The digestive system is very good at its job.

Oral semaglutide (with SNAC co-formulation): Approximately 0.4–0.5%, meaning about 1% of the subcutaneous dose achieves systemic circulation. This is considered a major achievement in peptide pharmaceutical engineering.

Topical peptides (without penetration enhancers): Highly variable but typically < 5% unless specifically engineered for trans-dermal absorption. Most topical peptide formulations are designed for local effects, not systemic absorption.

Intranasal peptides: Highly variable, ranging from 10–60% depending on the peptide and formulation. The nasal route can bypass first-pass metabolism, potentially achieving higher bioavailability than oral administration.

The key insight: bioavailability is not just a number. It is the primary determinant of whether a compound can produce systemic effects at all. If a dose has 0.5% bioavailability, 99.5% of what you took was destroyed or never absorbed. That remaining 0.5% has to be enough to bind receptors, trigger signaling, and produce the claimed effect. For many peptides with suspected low oral bioavailability, this threshold is never crossed.

↑ Back to top

First-Pass Metabolism: Why Oral Administration Is Fundamentally Different

To understand why oral administration of most peptides doesn’t work, you need to understand first-pass metabolism.

When you swallow something, it goes down your esophagus into your stomach, then into your small intestine. There, it’s absorbed across the intestinal epithelium into the bloodstream. But it doesn’t go directly into your general circulation—it goes into the portal blood, which carries it directly to your liver.

The liver is your body’s “detoxification and elimination” organ. It contains an array of enzymes designed to break down foreign compounds, extract useful components, and prevent bioaccumulation of potentially toxic substances. For many drugs and peptides, the liver either breaks them down enzymatically or chemically modifies them into a form your body can excrete.

This is called first-pass metabolism (or first-pass hepatic metabolism).

Here’s why it matters: if a compound is absorbed orally and immediately metabolized by the liver before it can reach your systemic circulation and target tissues, then oral bioavailability is effectively zero, even if it was technically absorbed.

IV and subcutaneous administration bypass first-pass metabolism. When you inject something intravenously, it goes directly into the systemic circulation and reaches the entire body (including target tissues) before any significant hepatic metabolism can occur. When you inject subcutaneously, it’s absorbed gradually into the bloodstream, but it still bypasses the portal circulation and reaches the body before the liver can eliminate it.

Oral administration does not bypass first-pass metabolism. Orally absorbed compounds face the liver first, before the rest of your body sees them.

For many peptides, the combination of (1) destruction in the stomach and intestine by digestive enzymes and (2) rapid hepatic metabolism of any molecule that does get absorbed means that oral administration produces almost no systemic exposure.

This is why oral BPC-157 data (if it exists) would not support claims about injectable BPC-157. The two routes produce fundamentally different exposures—one systemic, one mostly localized to the GI tract (and even then, only a tiny fraction of the dose makes it there intact).

↑ Back to top

Why the Same Compound via Different Routes Is Pharmacologically Different

Consider this thought experiment: GHK-Cu is a tripeptide that exists naturally in your body. You can apply it topically as a skincare cream, and research supports local skin benefits. You can also inject it subcutaneously as a systemic agent.

These sound like they’re the same compound. They are—chemically. But pharmacologically, they are different drugs.

GHK-Cu topical: Applied to skin as a cream or solution. The goal is local skin effects (collagen upregulation, wound healing, anti-inflammatory effects in skin tissue). Bioavailability is low—the peptide mostly stays localized to the skin and dermis. Systemic exposure is minimal or zero. This is the formulation with published cosmetic use data supporting safety and efficacy.

GHK-Cu subcutaneous: Injected into subcutaneous tissue with the goal of systemic circulation. The peptide is absorbed into the bloodstream and circulates throughout the body. Now it can potentially interact with receptors and cells in organs far from the injection site—liver, immune cells, vasculature, bone. The systemic exposure profile is completely different. The safety profile is different (you’re now exposing your entire body to the compound, not just skin). The efficacy for any given indication might be entirely different.

These two applications have different evidence bases. The topical data tells you nothing about the safety or efficacy of injected GHK-Cu in a healthy adult. The routes are different, the exposures are different, the pharmacology is different.

This principle applies to every peptide and every pair of routes. The compound is the same molecule, but the route creates a different pharmacological context.

Absorption kinetics matter. IV administration creates an immediate spike to peak concentration, then gradual decline. Subcutaneous administration creates a gentler rise to peak, followed by gradual decline. Oral administration creates an unpredictable and usually negligible exposure. These different concentration-time curves can create different receptor occupancy profiles, different tissue penetration, different durations of effect.

Peak concentration matters. IV infusion of a compound might create a 1,000 ng/mL peak concentration. Subcutaneous injection might create a 200 ng/mL peak. Oral might create a 10 ng/mL peak (if it gets absorbed at all). A receptor that’s maximally occupied at 200 ng/mL might be hyperactivated at 1,000 ng/mL, producing side effects. Or conversely, it might not be activated at all at 10 ng/mL. Different routes, different concentrations, different outcomes.

Distribution matters. An IV bolus reaches all tissues almost simultaneously. A subcutaneous injection reaches different tissues at different times as it’s absorbed and circulates. A topical application reaches skin first and might never reach deeper tissues. This affects which target tissues get the highest exposure and for how long.

Duration of effect matters. IV Aviptadil (VIP) has a half-life of 1–2 minutes in the bloodstream—it’s degraded almost immediately by neutral endopeptidase (NEP) and dipeptidyl peptidase-IV (DPP-IV). This means that IV infusion creates a brief, acute exposure. Subcutaneous self-administration has different absorption kinetics, creating a different time-concentration profile and therefore a different duration and quality of effect. Someone reading the Aviptadil clinical trial (IV infusion, n=40, Phase II) and concluding that subcutaneous VIP will produce similar results is making a fundamental pharmacokinetic error.

↑ Back to top

Peptidings Examples: How Route Determines Evidence Applicability

These examples demonstrate how route differences invalidate evidence transfer across routes.

GHK-Cu: The Two-Route Problem

GHK-Cu is a 3-amino-acid peptide (glycine-histidine-lysine) complexed with copper. It exists naturally in blood plasma and other tissues. It is Generally Recognized as Safe (GRAS) for topical and oral use by the FDA.

Topical GHK-Cu: Published cosmetic use data examines GHK-Cu in skincare formulations for collagen stimulation, skin barrier repair, and anti-aging effects. This evidence is robust for topical local effects. Tier 3 (Limited Human Data) based on cosmetic use research. The route is topical; the goal is skin-localized effects; the bioavailability is minimal or zero (it stays on the skin).

Injectable GHK-Cu: Some online communities discuss subcutaneous or intramuscular injection of GHK-Cu for systemic anti-aging effects, immune modulation, or wound healing. This application is completely different from the topical cosmetic data. There are no published controlled human trials of injectable GHK-Cu. The evidence base is Tier 5 (“It’s Complicated”) precisely because topical and injectable are different applications with different evidence bases entirely.

You cannot transfer topical cosmetic data to injectable systemic use. The routes are different, the bioavailability is different, the exposure is different, the pharmacology is different. This is the canonical example of route-dependent evidence misapplication.

VIP: IV Trial Data vs. Subcutaneous Self-Administration

VIP (vasoactive intestinal peptide) is a 28-amino-acid neuropeptide with endogenous functions throughout the gut, CNS, and immune system. It signals through VPAC1 and VPAC2 receptors.

IV infusion (Aviptadil clinical trial): A Phase II double-blind, placebo-controlled trial evaluated IV Aviptadil (recombinant VIP) in 40 patients with rheumatoid arthritis. Patients received intravenous infusions. IV administration produces 100% bioavailability and immediate peak concentration. VIP has a very short IV half-life: 1–2 minutes. It is rapidly degraded by neutral endopeptidase and DPP-IV. This means IV infusion creates a brief but immediate and complete systemic exposure.

Subcutaneous self-administration (community CIRS protocols): Outside of clinical settings, some people with Chronic Inflammatory Response Syndrome (CIRS) self-administer VIP subcutaneously. Subcutaneous injection creates a different absorption kinetics, a different peak concentration, a different tissue penetration pattern, and a different duration of effect than IV infusion.

The Aviptadil IV trial data does not predict whether subcutaneous VIP will be safe or effective for rheumatoid arthritis or CIRS. The routes are different. The pharmacokinetics are completely different. Someone reading the trial and assuming subcutaneous efficacy is committing the cardinal evidence error: assuming evidence from one route supports claims about another route.

Additionally, hypotension is a predictable pharmacological consequence of all VIP administration (VIP causes vasodilation). IV infusion can produce hypotension that’s observable in real time, with medical personnel present. Subcutaneous self-administration could produce hypotension without medical supervision or the ability to manage it.

BPC-157: Oral vs. Injectable Evidence

BPC-157 is a synthetic peptide derived from gastric juice (body protection compound-157). It has an exceptionally strong preclinical portfolio—more than 100 rodent studies across injury models (tendons, ligaments, muscle, bone, gut).

Oral BPC-157: Some of the preliminary human evidence for BPC-157 comes from oral formulations in inflammatory bowel disease (IBD) patients. These formulations include excipients specifically designed for gut delivery and local intestinal effects. The goal is local gastrointestinal effects, and the exposure is primarily localized to the GI tract (any systemic absorption is incidental).

Injectable BPC-157: The preclinical literature is dominated by directly injected or locally administered BPC-157 (injected into wounds, tendons, fracture sites, etc.). These studies produce extremely high local concentrations at the target tissue. The injectable route would produce systemic circulation, distributing BPC-157 throughout the body, including to tissues not exposed in the oral IBD studies.

The oral IBD studies do not support claims about systemically injected BPC-157. The routes are different. The bioavailability is different. The target tissues are different. The formulations are different (oral uses gut-delivery excipients; injectable would be a simple aqueous solution). The evidence is different.

Semaglutide: The Success Story of Route-Appropriate Engineering

Semaglutide (FDA-approved GLP-1 receptor agonist) is the exception that proves the rule.

Subcutaneous semaglutide (Ozempic, Wegovy): Standard formulation. Administered weekly via subcutaneous injection. High bioavailability (dose-dependent, but approaching 100% of the injected dose for the drug substance). Long half-life (~7 days) due to a C18 fatty diacid tail that increases plasma binding and resistance to DPP-IV degradation. The slow, sustained exposure allows weekly dosing.

Oral semaglutide (Rybelsus): Also FDA-approved. Much lower bioavailability than subcutaneous. Requires co-formulation with SNAC (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate), a permeation enhancer. Achieves only ~0.4–0.5% bioavailability. This required much higher oral doses (up to 14 mg) to achieve comparable efficacy to lower subcutaneous doses. The pharmacokinetics are different—lower peak concentration, less stable steady-state exposure, requires daily dosing instead of weekly.

This is the rare case where a compound successfully bridges two routes with regulatory approval for both. But note: oral semaglutide is a separate pharmaceutical entity (same active drug, different formulation strategy, dramatically different bioavailability). You cannot apply subcutaneous semaglutide data directly to oral semaglutide. They required separate clinical trial programs to demonstrate efficacy and safety.

↑ Back to top

Why You Cannot Transfer Evidence Across Routes: A Principle, Not a Rule

The fundamental principle: a study showing efficacy via one route does not support claims about efficacy via another route.

This is not a guideline that applies sometimes. It is a principle that applies always. The reason is pharmacological. Different routes create different exposures—different peak concentrations, different concentration-time curves, different tissue penetration, different duration of effects. The pathway from pharmacological exposure to clinical outcome is specific to that exposure. A different exposure pathway produces a different outcome—either no effect, a different magnitude of effect, or adverse effects.

Some people resist this principle because it feels overly restrictive. If a compound worked via IV infusion, shouldn’t we be able to make it work via another route? Maybe. But not based on the IV data alone. You would need new evidence demonstrating that the alternative route produces sufficient exposure to the target tissue to trigger the same mechanism.

This is why the single most common evidence error in peptide science is claiming that evidence from one route supports efficacy via another route.

Examples from Peptidings:

• “GHK-Cu topical data supports injectable GHK-Cu claims.” False. Different routes, different applications, different evidence bases.
• “Aviptadil IV trial data supports subcutaneous VIP self-experimentation.” False. IV and subcutaneous have different pharmacokinetics, different peak concentrations, different durations of effect.
• “BPC-157 oral IBD studies support injectable BPC-157 for joint injuries.” False. Different routes, different formulations, different target tissues, different evidence bases.

Each of these claims sounds plausible because the compound is the same. But plausibility is not evidence. The route is different. That difference determines whether the evidence applies.

↑ Back to top

The Intravitreal Exception: A Separate Pharmacological Universe

Intravitreal injection is unique among peptide administration routes because it creates a completely isolated pharmacological space—the eye.

The blood-retinal barrier prevents systemic circulation. When you inject a peptide directly into the vitreous humor, it stays in the eye. Concentrations in the vitreous are extremely high (sometimes 1,000+ times higher than systemic levels for a given dose). But systemic exposure is negligible—the compound is not circulating throughout the body.

This creates a distinct pharmacological context. A peptide that’s intravitreally injected cannot produce systemic effects (it never enters systemic circulation). It also cannot cause systemic toxicity (there’s no systemic exposure). The safety profile is confined to ocular toxicity, retinal compatibility, and vitreous clarity. The efficacy is confined to effects on retinal cells, photoreceptors, and other intraocular structures.

This matters for the Vision/Ocular peptide cluster on Peptidings. Any peptide being researched for intravitreal injection requires its own evidence base distinct from systemic delivery routes. The copper/teal warning on the Vision cluster hub exists because intravitreal copper exposure (from GHK-Cu or other copper-binding peptides) produces different toxicity profiles than systemic copper exposure.

If a researcher publishes data showing that a peptide is safe and efficacious when injected intravitreally, you cannot assume it’s safe or efficacious when injected subcutaneously. The route changed. The entire pharmacological context changed. New evidence would be needed.

↑ Back to top

Implications for Readers: The Question You Must Always Ask

When you read any claim about a peptide’s efficacy, safety, or effects, the first interpretive step is this: Determine what route was used in the cited evidence.

Then ask: Does that route match the route being discussed?

If yes, the evidence might be applicable (subject to other considerations like study design, population relevance, statistical significance, etc.).

If no, the evidence does not transfer. The claim requires separate evidence from the relevant route, or it is unsupported.

This single question—”What route?”—prevents the vast majority of evidence misinterpretations in peptide science.

Here are some real-world applications:

Scenario 1: You read that GHK-Cu accelerates skin healing.

• Question: What route? Answer: Topical application in cosmetic formulations.
• Implication: You can consider this evidence for topical GHK-Cu skincare use. You cannot infer anything about injectable GHK-Cu safety or efficacy for systemic use.

Scenario 2: You read that BPC-157 heals tendons.

• Question: What route? Answer: Direct injection into rat tendons.
• Implication: This is preclinical evidence in a localized-injection model. It does not tell you about bioavailability, systemic pharmacokinetics, or human efficacy. You would need human evidence via the route of administration you’re considering (subcutaneous? oral? localized injection into your own tendon?).

Scenario 3: You read that VIP helps rheumatoid arthritis.

• Question: What route? Answer: IV infusion in a Phase II clinical trial (n=40).
• Implication: You have evidence for IV infusion in a specific disease population. You do not have evidence for subcutaneous self-administration in rheumatoid arthritis, CIRS, or any other condition. The pharmacokinetics are different.

Scenario 4: You’re considering oral semaglutide.

• Question: What route are the published efficacy studies using? Answer: Both oral and subcutaneous, but in separate trials.
• Implication: Oral semaglutide was tested separately from subcutaneous semaglutide. You have efficacy evidence specific to the oral route. You can rely on oral-specific evidence; you cannot assume subcutaneous data applies to oral, or vice versa.

By asking “What route?” first, you immediately distinguish between applicable and inapplicable evidence. You also protect yourself from the subtle version of this error: assuming that evidence from a more “legitimate” route (clinical trials are more prestigious than preclinical animal studies) automatically justifies claims about a different route.

Prestige of the evidence doesn’t matter. Route applicability matters.

↑ Back to top

FAQ: Questions About Route and Evidence

Related Guides

• Evidence Levels Explained—Understanding Tier 1 through Tier 5 evidence, and how route factors into tier assignment
• Bioavailability and Half-Life—Deep dive into how these pharmacokinetic parameters change by route
• Reading a Clinical Trial: What Study Design Actually Tells You—Why the route used in a trial is a critical detail to extract
• Common Evidence Misinterpretations—This guide is foundational to understanding why one of the most common errors is assuming evidence from one route supports claims about another
• GHK-Cu (compound article)—Example of a Tier 5 (“It’s Complicated”) compound where route entirely determines the evidence base
• VIP (compound article)—Aviptadil IV clinical trial vs. subcutaneous self-administration: a case study in route-dependent pharmacology
• BPC-157 (compound article)—Oral formulations in IBD vs. injectable systemic use: different applications, different evidence
• Semaglutide (compound article)—The rare case where a peptide is successfully FDA-approved via two routes, with separate evidence bases for each

↑ Back to top

Summary

Route of administration is not a detail or convenience. It is a determinant of the drug itself.

The same peptide molecule via different routes produces different bioavailability, different absorption kinetics, different peak concentrations, different tissue distributions, different durations of effect, and different safety profiles. These differences mean that evidence from one route does not automatically support claims about another route.

This is the single most commonly overlooked distinction in peptide evidence interpretation, and it is the foundation of the most prevalent evidence errors: assuming IV trial data supports subcutaneous use, assuming topical efficacy data supports systemic injection, assuming oral efficacy data transfers across routes.

When you read any claim about a peptide, ask yourself: “What route was tested?” If the answer does not match the route being discussed, the evidence does not transfer. The claim requires separate evidence, or it is unsupported.

This single question—asked consistently, applied rigorously—prevents the vast majority of evidence misinterpretations in peptide science and is the reason this principle matters more than you might think.

—

↑ Back to top

---